JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN)

Int J Hematol. 2017 Nov;106(5):591-611. doi: 10.1007/s12185-017-2330-1. Epub 2017 Sep 21.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Algorithms
  • Aniline Compounds / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Aspirin / administration & dosage
  • Blood Transfusion
  • Dasatinib / administration & dosage
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Hydroxyurea / administration & dosage
  • Imidazoles / administration & dosage
  • Japan
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / classification
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy
  • Myeloproliferative Disorders* / classification
  • Myeloproliferative Disorders* / genetics
  • Myeloproliferative Disorders* / therapy
  • Nitriles / administration & dosage
  • Phlebotomy
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrazoles / administration & dosage
  • Pyridazines / administration & dosage
  • Pyrimidines / administration & dosage
  • Quinazolines / administration & dosage
  • Quinolines / administration & dosage
  • Risk

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Imidazoles
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridazines
  • Pyrimidines
  • Quinazolines
  • Quinolines
  • ponatinib
  • bosutinib
  • ruxolitinib
  • Protein-Tyrosine Kinases
  • nilotinib
  • anagrelide
  • Aspirin
  • Dasatinib
  • Hydroxyurea